ClinicalTrials.gg

Program

Tamsulosin

Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.

Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.

Furthest: phase 4, since Sep 18, 201456 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim140 open or runningphase 4since Sep 18, 2014Jun 19, 2006none ahead
Astellas Pharma100 open or runningphase 4since Mar 17, 2016Jul 25, 2007none ahead
GlaxoSmithKline90 open or runningphase 4since Feb 10, 2011Aug 24, 2004none ahead
Hanmi Pharmaceutical50 open or runningphase 3since Feb 23, 2015Sep 4, 2014none ahead
Chong Kun Dang Pharmaceutical30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Menarini Group33 open or runningphase 1since Jul 22, 2025Jul 22, 2025none ahead
GL Pharm Tech20 open or runningphase 3since Nov 11, 2014Feb 24, 2014none ahead
Jeil Pharmaceutical20 open or runningphase 3since Nov 21, 2016Jul 1, 2014none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jun 22, 2010Jun 22, 2010none ahead
adium10 open or runningno phasesince Jul 7, 2026Jul 7, 2026none ahead
ascension-health10 open or runningphase 4since Nov 5, 2016Nov 5, 2016none ahead
Dexa Medica Group10 open or runningphase 1since Aug 14, 2024Aug 14, 2024none ahead
getz-pharma10 open or runningphase 4since Jul 7, 2023Jul 7, 2023none ahead
IlDong Pharmaceutical10 open or runningphase 3since Jul 22, 2016Jul 22, 2016none ahead
neotract-inc11 open or runningphase 4since Jul 9, 2021Jul 9, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Aug 24, 2004.

  1. Oct 1, 2015Phase 3 study in Urological ManifestationsBoehringer Ingelheim · NCT02573311 · 1,117 enrolled · United States
  2. Dec 16, 2015Phase 1 study in Prostatic HyperplasiaAstellas Pharma · NCT02634489 · 46 enrolled · Netherlands
  3. Jan 29, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02715401 · 36 enrolled
  4. Feb 24, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02712411 · 30 enrolled · Korea, Republic of
  5. Mar 17, 2016Phase 4 study in Lower Urinary Tract SymptomsAstellas Pharma · NCT02715024 · 52 enrolled · Taiwan
  6. Jul 22, 2016IlDong Pharmaceutical's first study: phase 3 study in Prostatic HyperplasiaNew to IlDong PharmaceuticalIlDong Pharmaceutical · NCT02862483 · 330 enrolled · Korea, Republic of
  7. Nov 5, 2016ascension-health's first study: phase 4 study in Postoperative Urinary RetentionNew to ascension-healthascension-health · NCT02958878 · 210 enrolled
  8. Nov 21, 2016Phase 3 study in Lower Urinary Tract SymptomsJeil Pharmaceutical · NCT02972268 · 780 enrolled · Korea, Republic of
  9. Jul 9, 2021neotract-inc's first study: phase 4 study in BPHNew to neotract-incneotract-inc · NCT04987892 · 250 planned · United States
  10. Jul 7, 2023getz-pharma's first study: phase 4 study in Ureteric Stone of Lower Third of UreterNew to getz-pharmagetz-pharma · NCT05977647 · 240 enrolled · Pakistan
  11. Aug 14, 2024Dexa Medica Group's first study: phase 1 study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT06558032 · 28 enrolled · Indonesia
  12. Jul 22, 2025Menarini Group's first study: phase 1 study in Healthy VolunteersNew to Menarini GroupMenarini Group · NCT07091669 · 46 enrolled · Armenia
  13. Aug 21, 20252 phase 1 studiesMenarini Group · NCT07146711, NCT07156916
  14. Jul 7, 2026adium's first study: no phase study in BioequivalenceNew to adiumadium · NCT07698288 · 66 enrolled · Mexico

TargetBeta

“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410
PrazosinrulePfizerphase 34

Studies

All 56 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07698288Bioequivalence · Mexico–CompletedadiumApr 16, 202666
NCT07156916Healthy Volunteer Male Subjects · Armenia1RecruitingMenarini GroupMar 1, 202646
NCT07146711Healthy Adult Males Volunteers · Armenia1Active, not recruitingMenarini GroupOct 1, 202533
NCT07091669Healthy Volunteers · Armenia1Active, not recruitingMenarini GroupAug 1, 202546
NCT06558032Healthy · Indonesia1CompletedDexa Medica GroupDec 16, 202328
NCT05977647Ureteric Stone of Lower Third of Ureter · Pakistan4Completedgetz-pharmaMay 30, 2025240
NCT04987892BPH · United States4Recruitingneotract-incMay 2025250
NCT02972268Lower Urinary Tract Symptoms · Korea, Republic of3CompletedJeil PharmaceuticalNov 2, 2017780
NCT02958878Postoperative Urinary Retention4Completedascension-healthNov 30, 2018210
NCT02862483Prostatic Hyperplasia · Korea, Republic of3UNKNOWNIlDong PharmaceuticalMar 2017330
NCT02715024Lower Urinary Tract Symptoms · Taiwan4CompletedAstellas PharmaApr 201152
NCT02712411Erectile Dysfunction · Korea, Republic of1CompletedHanmi PharmaceuticalAug 201530
NCT02715401Erectile Dysfunction1CompletedHanmi PharmaceuticalNov 201536
NCT02634489Prostatic Hyperplasia · Netherlands1CompletedAstellas PharmaJul 200946
NCT02573311Urological Manifestations · United States3CompletedBoehringer IngelheimAug 1, 20161,117
NCT03246880Prostatic Hyperplasia · Korea, Republic of3CompletedChong Kun Dang PharmaceuticalApr 2016455
NCT02529800Healthy1CompletedHanmi PharmaceuticalOct 201524
NCT02417844Prostatic Hyperplasia1CompletedBoehringer IngelheimMay 201534
NCT02390882Prostatic Hyperplasia · Korea, Republic of3CompletedHanmi PharmaceuticalMay 2015494
NCT02303769Prostatic Hyperplasia · Korea, Republic of3CompletedGL Pharm TechMay 2015309
NCT02266537Healthy1CompletedBoehringer IngelheimFeb 200697
NCT02266524Urination Disorders1CompletedBoehringer IngelheimApr 200548
NCT02266511Healthy1CompletedBoehringer IngelheimSep 199930
NCT02264184Healthy1CompletedBoehringer IngelheimDec 200824
NCT02244294Prostatic Hyperplasia2CompletedBoehringer IngelheimJun 2005176
NCT02244281Lower Urinary Tract Symptoms2CompletedBoehringer IngelheimNov 200374
NCT02244255Prostatic Hyperplasia4CompletedBoehringer IngelheimJun 20001,993
NCT02244242Prostatic Hyperplasia4CompletedBoehringer IngelheimAug 1999493
NCT02244229Prostatic Hyperplasia4CompletedBoehringer IngelheimNov 2000403
NCT02247518Healthy · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalOct 201416
NCT02247505Healty Male Volunteers · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalOct 201429
NCT02239484Erectile Dysfunction · Korea, Republic of1CompletedHanmi PharmaceuticalSep 201430
NCT02180997Prostatic Hyperplasia · Korea, Republic of1CompletedJeil PharmaceuticalMar 201536
NCT02169713Healthy Subjects · Germany1CompletedAstellas PharmaAug 201420
NCT02138773Healthy · China1CompletedAstellas PharmaJul 201480
NCT02072213Healthy · Korea, Republic of1CompletedGL Pharm TechJan 201436
NCT02058576Urologic Diseases · United Kingdom1CompletedGlaxoSmithKlineJan 2, 201577
NCT02052713Urologic Diseases · United Kingdom1CompletedGlaxoSmithKlineDec 29, 201478
NCT02058368Prostatic Hyperplasia · China, Japan, Korea, Republic of and more3CompletedGlaxoSmithKlineMar 3, 2017607
NCT01957189Prostatic Hyperplasia · China1CompletedGlaxoSmithKlineJan 22, 201424
NCT01953887EC905 · United Kingdom1CompletedAstellas PharmaJul 201030
NCT01777269Prostatic Hyperplasia · Australia, France, Germany and more4CompletedGlaxoSmithKlineApr 5, 2016489
NCT01726270Lower Urinary Tract Symptoms · United States2CompletedBoehringer IngelheimMar 2013689
NCT01657851Prostatic Hyperplasia · Russian Federation1CompletedGlaxoSmithKlineDec 5, 201235
NCT01673490Prostatic Hyperplasia · Vietnam4TerminatedGlaxoSmithKlineMar 20, 201559
NCT01489696Cardiovascular · United Kingdom1CompletedAstellas PharmaFeb 201148
NCT01294592Prostatic Hyperplasia · France, Germany, Greece and more4CompletedGlaxoSmithKlineOct 17, 2013742
NCT01149746Healthy · Canada1CompletedTeva Pharmaceutical IndustriesDec 200432
NCT01149733Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200432
NCT01021332Lower Urinary Tract Symptoms · Austria, Belarus, Belgium and more3CompletedAstellas PharmaDec 14, 20111,067
NCT01018511Prostatic Hyperplasia · Austria, Belarus, Belgium and more3CompletedAstellas PharmaMar 1, 20111,334
NCT00796614Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more3CompletedBoehringer IngelheimFeb 2009231
NCT00510406Lower Urinary Tract Symptoms · Austria, Czech Republic, Denmark and more2CompletedAstellas PharmaSep 2007919
NCT00507455Lower Urinary Tract Symptoms · United States, Belgium, Czech Republic and more2CompletedAstellas PharmaAug 2008222
NCT00340704Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more2CompletedBoehringer IngelheimJun 2009143
NCT00090103Prostatic Hyperplasia · United States, Argentina, Belgium and more3CompletedGlaxoSmithKlineApr 20094,844

How it is read

Names in the registry

  • “Tamsulosin”, 12 entries
  • “tamsulosin hydrochloride”, 6 entries
  • “Tamsulosin (0.4 mg/j)”, 5 entries
  • “tamsulosin”, 4 entries
  • “HIP1402”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.